Arbutus Biopharma (NASDAQ:ABUS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, January 3rd.
According to Zacks, “Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company’s products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. “
Other analysts have also issued research reports about the company. BidaskClub raised Arbutus Biopharma from a “strong sell” rating to a “sell” rating in a report on Thursday, December 21st. Chardan Capital reaffirmed a “buy” rating on shares of Arbutus Biopharma in a report on Wednesday, September 13th. ValuEngine lowered Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Leerink Swann reaffirmed a “market perform” rating and issued a $5.00 price objective (up previously from $4.00) on shares of Arbutus Biopharma in a report on Tuesday, November 7th. Finally, JMP Securities reaffirmed an “outperform” rating and issued a $13.00 price objective (up previously from $12.00) on shares of Arbutus Biopharma in a report on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $12.50.
Arbutus Biopharma (NASDAQ ABUS) remained flat at $$5.05 during mid-day trading on Wednesday. The company’s stock had a trading volume of 133,300 shares, compared to its average volume of 273,303. The company has a debt-to-equity ratio of 0.08, a current ratio of 11.03 and a quick ratio of 11.03. Arbutus Biopharma has a fifty-two week low of $2.35 and a fifty-two week high of $8.25. The stock has a market cap of $278.01, a PE ratio of -1.01 and a beta of 1.07.
A number of large investors have recently added to or reduced their stakes in the business. RTW Investments LP grew its holdings in Arbutus Biopharma by 1.1% during the third quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock valued at $32,651,000 after purchasing an additional 56,457 shares during the period. Point72 Asset Management L.P. bought a new stake in Arbutus Biopharma during the third quarter valued at about $1,393,000. Victory Capital Management Inc. bought a new stake in Arbutus Biopharma during the second quarter valued at about $478,000. OxFORD Asset Management LLP grew its holdings in Arbutus Biopharma by 49.2% during the third quarter. OxFORD Asset Management LLP now owns 124,273 shares of the biopharmaceutical company’s stock valued at $778,000 after purchasing an additional 40,963 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Arbutus Biopharma by 2.7% during the second quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 2,035 shares during the period. 59.97% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Arbutus Biopharma (NASDAQ:ABUS) Downgraded to Sell at Zacks Investment Research” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/01/11/arbutus-biopharma-abus-downgraded-by-zacks-investment-research-to-sell.html.
About Arbutus Biopharma
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Get a free copy of the Zacks research report on Arbutus Biopharma (ABUS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.